 |
|
|
| |
Update from Study A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children aged 2-<18 years
|
| |
| |
Reported by Jules Levin
IAS 2013 June 30-July 3 Kulala Lumpur
M Vourvahis,1 L McFadyen,2 T Checchio,3 C Giaquinto,4 L Keet,5 SR Valluri,1 A Fang,1 G Mukwaya,1 J Heera6
1Pfizer Inc, Specialty Care, New York, NY, USA; 2Pfizer Inc, Primary Care, Sandwich, Kent, UK; 3Pfizer Inc, Primary Care, Groton, CT, USA;
4Department of Pediatrics, University of Padova, Padova, Italy; 5Department Pediatrics, University of the Free State, Bloemfontein, South
Africa; 6Pfizer Inc, Specialty Care, Groton, CT, USA
|
| |
|
|
|
|
|
